929643-09-4Relevant academic research and scientific papers
Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: Novel CYP17 inhibitors for the treatment of prostate cancer
Pinto-Bazurco Mendieta, Mariano A. E.,Negri, Matthias,Jagusch, Carsten,Müller-Vieira, Ursula,Lauterbach, Thomas,Hartmann, Rolf W.
supporting information; experimental part, p. 5009 - 5018 (2009/07/04)
Abiraterone, a steroidal cytochrome P450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer. Since steroidal compounds often show side
5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators
-
Page/Page column 16, (2010/11/26)
Compounds of formula I are provided, wherein R1-R9 and n are defined herein, and pharmaceutical compositions and kits containing these compounds. Also provided are methods of inducing contraception, providing hormone replacement ther
5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
-
Page/Page column 17, (2010/11/26)
Compounds of formula I or II are provided, wherein R1—R8 are defined herein, and pharmaceutical compositions and kits containing these compounds. Also provides are methods of inducing contraception, providing hormone replacement ther
